Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $198.07

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have received an average rating of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $198.0714.

A number of equities research analysts recently commented on PVLA shares. Mizuho increased their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group increased their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. UBS Group reissued a “buy” rating and set a $143.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. Oppenheimer reissued an “outperform” rating and set a $200.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. Finally, Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 24th.

Insider Activity at Palvella Therapeutics

In related news, Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were acquired at an average price of $125.00 per share, for a total transaction of $500,000.00. Following the purchase, the director owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The disclosure for this sale is available in the SEC filing. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC increased its stake in Palvella Therapeutics by 8.5% during the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after purchasing an additional 70,000 shares in the last quarter. Frazier Life Sciences Management L.P. increased its stake in Palvella Therapeutics by 4.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after purchasing an additional 32,388 shares in the last quarter. First Light Asset Management LLC increased its stake in Palvella Therapeutics by 30.9% during the 4th quarter. First Light Asset Management LLC now owns 709,141 shares of the company’s stock valued at $74,226,000 after purchasing an additional 167,597 shares in the last quarter. Vanguard Group Inc. increased its stake in Palvella Therapeutics by 13.3% during the 4th quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after purchasing an additional 65,960 shares in the last quarter. Finally, State Street Corp increased its stake in Palvella Therapeutics by 206.3% during the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after purchasing an additional 283,211 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $119.86 on Friday. The company has a 50 day moving average price of $107.85 and a 200-day moving average price of $93.50. Palvella Therapeutics has a fifty-two week low of $18.23 and a fifty-two week high of $151.18. The stock has a market capitalization of $1.72 billion, a PE ratio of -32.31 and a beta of -0.21.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.13). Equities research analysts forecast that Palvella Therapeutics will post -3.69 EPS for the current year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.